Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. May 26, 2022; 10(15): 4985-4990
Published online May 26, 2022. doi: 10.12998/wjcc.v10.i15.4985
Published online May 26, 2022. doi: 10.12998/wjcc.v10.i15.4985
Bone flare after initiation of novel hormonal therapy in patients with metastatic hormone-sensitive prostate cancer: A case report
Ke-Hao Li, Yuan-Cheng Du, Dong-Yu Yang, Xin-Yuan Yu, Department of Clinic, Weifang Medical University, Weifang 261000, Shandong Province, China
Xue-Ping Zhang, Yong-Xiang Li, Liang Qiao, Department of Urology, Weifang People's Hospital, Weifang 261000, Shandong Province, China
Author contributions: Li KH reviewed the literature, and contributed to manuscript drafting; Du YC, Yu XY and Li YX contributed to manuscript drafting; Zhang XP and Yang DY obtained informed consent; Qiao L was responsible for the revision of the manuscript; and All authors gave final approval for the submitted version.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Liang Qiao, MD, PhD, Chief Doctor, Professor, Department of Urology, Weifang People's Hospital, No. 151 Guangwen Street, Kuiwen District, Weifang 261000, Shandong Province, China. lysanjin@163.com
Received: October 30, 2021
Peer-review started: October 30, 2021
First decision: February 14, 2022
Revised: March 4, 2022
Accepted: March 25, 2022
Article in press: March 25, 2022
Published online: May 26, 2022
Processing time: 206 Days and 9.8 Hours
Peer-review started: October 30, 2021
First decision: February 14, 2022
Revised: March 4, 2022
Accepted: March 25, 2022
Article in press: March 25, 2022
Published online: May 26, 2022
Processing time: 206 Days and 9.8 Hours
Core Tip
Core Tip: In 2018, prostate cancer was ranked as the fifth leading cause of cancer-related deaths in men, worldwide. Some of such cases are metastatic hormone-sensitive prostate cancers (mHSPC) and Apalutamide has been shown to improve survival in such patients. However, a “bone-flare” phenomenon may occur during management with apalutamide. We describe a case of mHSPC with this phenomenon after apalutamide and androgen deprivation therapy, and thus demonstrate the importance of multiple bone imaging modalities, radionuclide bone imaging, magnetic resonance imaging, prostate-specific antigen, prostate-specific membrane antigen positron emission tomography – computed tomography, in determining the treatment course in such patients.